Tesamorelin 2mg
$75.00
out of stock
Description
Overview
What Is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone analog used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism, but has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury.
Benefits of Tesamorelin:
- Significant increases in IGF-1 (Growth Hormone)
- Reduction of visceral fat, especially around the stomach
- Increase in lean muscle mass and tones the body
- Benefits overall cardiovascular health
- Increases recovery post-workout
Scientific Information
Tesamorelin (tes” a moe rel’ in) is a synthetic 44 amino acid polypeptide analog of growth hormone-releasing hormone (GHRH). The N terminal portion of the molecule has been modified to improve its stability and pharmacokinetics in comparison to native GHRH. Tesamorelin activates GHRH receptors in the pituitary which leads to the synthesis and release of growth hormone that acts on multiple cells of the body, including hepatocytes, where it stimulates the production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of the effects of growth hormone, which in the liver include growth, inhibition of programmed cell death, glucose uptake, and lipolysis. Serum IGF-1 levels tend to be low in patients with obesity, diabetes, and particularly in those with lipodystrophy.
Tesamorelin was evaluated Tesamorelin and found it effective in decreasing visceral adiposity in patients with lipodystrophy linked to antiretroviral therapy for human immunodeficiency virus (HIV) infection. As a result, the FDA approved Tesamorelin in 2010 to reduce excess abdominal fat in HIV-infected patients with antiviral therapy-related lipodystrophy. In addition, researchers are exploring its potential as a treatment for insulin resistance, obesity, and nonalcoholic fatty liver disease (NAFLD). Currently, Tesamorelin is available in solution form in vials of 1 mg/mL under the brand name Egrifta.
Specifically, the recommended dose is 2 mg daily, administered via subcutaneous injection. Moreover, side effects are uncommon but can include injection site reactions, itching, arthralgia, myalgia, and peripheral edema. Importantly, Tesamorelin raises IGF-1 levels, and monitoring for elevations during therapy is recommended. However, potential rare adverse events include the stimulation of malignant tumor growth, glucose intolerance, diabetes, and hypersensitivity reactions.
Research Highlights
Tesamorelin, a synthetic analog of growth hormone-releasing hormone (GHRH), plays a key role in regulating growth hormone (GH) in the body. The FDA has approved it for treating visceral adiposity in HIV patients. This article explores its fat-reducing effects. Tesamorelin has proven to be a safe and effective treatment for excess fat in HIV-infected patients, showing statistically significant improvements in fat content and quality of life in well-controlled trials. Common side effects include pain and injection site reactions. Researchers have also studied it in other conditions, such as NAFLD, but it is not approved for non-HIV-positive patients.
References
- Tesamorelin – PubMed: https://www.ncbi.nlm.nih.gov/books/NBK548730/
- Tesamorelin Therapy – Novagenix: https://novagenix.org/more/tesamorelin-therapy
- Tesamorelin Overview – Weight Loss and Vitality: https://www.weightlossandvitality.com/blog/tesamorelin-a-growth-hormone-peptide-overview
Additional information
